These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

222 related articles for article (PubMed ID: 25916394)

  • 1. Immunohistochemical expression of stem cell markers in pheochromocytomas/paragangliomas is associated with SDHx mutations.
    Oudijk L; Neuhofer CM; Lichtenauer UD; Papathomas TG; Korpershoek E; Stoop H; Oosterhuis JW; Smid M; Restuccia DF; Robledo M; de Cubas AA; Mannelli M; Gimenez-Roqueplo AP; Dinjens WN; Beuschlein F; de Krijger RR
    Eur J Endocrinol; 2015 Jul; 173(1):43-52. PubMed ID: 25916394
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The mTORC1 Complex Is Significantly Overactivated in SDHX-Mutated Paragangliomas.
    Oudijk L; Papathomas T; de Krijger R; Korpershoek E; Gimenez-Roqueplo AP; Favier J; Canu L; Mannelli M; Rapa I; Currás-Freixes M; Robledo M; Smid M; Papotti M; Volante M
    Neuroendocrinology; 2017; 105(4):384-393. PubMed ID: 28122379
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical significance and peculiarities of succinate dehydrogenase B and hypoxia inducible factor 1α expression in parasympathetic versus sympathetic paragangliomas.
    Bernardo-Castiñeira C; Sáenz-de-Santa-María I; Valdés N; Astudillo A; Balbín M; Pitiot AS; Jiménez-Fonseca P; Scola B; Tena I; Molina-Garrido MJ; Sevilla MA; Beristein E; Forga L; Villabona C; Oriola J; Halperin I; Suarez C; Chiara MD
    Head Neck; 2019 Jan; 41(1):79-91. PubMed ID: 30549360
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Overexpression of miR-210 is associated with SDH-related pheochromocytomas, paragangliomas, and gastrointestinal stromal tumours.
    Tsang VH; Dwight T; Benn DE; Meyer-Rochow GY; Gill AJ; Sywak M; Sidhu S; Veivers D; Sue CM; Robinson BG; Clifton-Bligh RJ; Parker NR
    Endocr Relat Cancer; 2014 Jun; 21(3):415-26. PubMed ID: 24623741
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Metabolome profiling by HRMAS NMR spectroscopy of pheochromocytomas and paragangliomas detects SDH deficiency: clinical and pathophysiological implications.
    Imperiale A; Moussallieh FM; Roche P; Battini S; Cicek AE; Sebag F; Brunaud L; Barlier A; Elbayed K; Loundou A; Bachellier P; Goichot B; Stratakis CA; Pacak K; Namer IJ; Taïeb D
    Neoplasia; 2015 Jan; 17(1):55-65. PubMed ID: 25622899
    [TBL] [Abstract][Full Text] [Related]  

  • 6. SDHD immunohistochemistry: a new tool to validate SDHx mutations in pheochromocytoma/paraganglioma.
    Menara M; Oudijk L; Badoual C; Bertherat J; Lepoutre-Lussey C; Amar L; Iturrioz X; Sibony M; Zinzindohoué F; de Krijger R; Gimenez-Roqueplo AP; Favier J
    J Clin Endocrinol Metab; 2015 Feb; 100(2):E287-91. PubMed ID: 25405498
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Genotype and tumor locus determine expression profile of pseudohypoxic pheochromocytomas and paragangliomas.
    Shankavaram U; Fliedner SM; Elkahloun AG; Barb JJ; Munson PJ; Huynh TT; Matro JC; Turkova H; Linehan WM; Timmers HJ; Tischler AS; Powers JF; de Krijger R; Baysal BE; Takacova M; Pastorekova S; Gius D; Lehnert H; Camphausen K; Pacak K
    Neoplasia; 2013 Apr; 15(4):435-47. PubMed ID: 23555188
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Increased SSTR2A and SSTR3 expression in succinate dehydrogenase-deficient pheochromocytomas and paragangliomas.
    Elston MS; Meyer-Rochow GY; Conaglen HM; Clarkson A; Clifton-Bligh RJ; Conaglen JV; Gill AJ
    Hum Pathol; 2015 Mar; 46(3):390-6. PubMed ID: 25554089
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunohistochemical Staining for SOX10 and SDHB in SDH-Deficient Paragangliomas Indicates that Sustentacular Cells Are Not Neoplastic.
    Powers JF; Tischler AS
    Endocr Pathol; 2020 Sep; 31(3):307-309. PubMed ID: 32562155
    [No Abstract]   [Full Text] [Related]  

  • 10. LncRNA expression and SDHB mutations in pheochromocytomas and paragangliomas.
    Li H; Hardin H; Zaeem M; Huang W; Hu R; Lloyd RV
    Ann Diagn Pathol; 2021 Dec; 55():151801. PubMed ID: 34461576
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeting pheochromocytoma/paraganglioma with polyamine inhibitors.
    Rai SK; Bril F; Hatch HM; Xu Y; Shelton L; Kalavalapalli S; Click A; Lee D; Beecher C; Kirby A; Kong K; Trevino J; Jha A; Jatav S; Kriti K; Luthra S; Garrett TJ; Guingab-Cagmat J; Plant D; Bose P; Cusi K; Hromas RA; Tischler AS; Powers JF; Gupta P; Bibb J; Beuschlein F; Robledo M; Calsina B; Timmers H; Taieb D; Kroiss M; Richter S; Langton K; Eisenhofer G; Bergeron R; Pacak K; Tevosian SG; Ghayee HK
    Metabolism; 2020 Sep; 110():154297. PubMed ID: 32562798
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Current views on cell metabolism in SDHx-related pheochromocytoma and paraganglioma.
    Vicha A; Taieb D; Pacak K
    Endocr Relat Cancer; 2014 Jun; 21(3):R261-77. PubMed ID: 24500761
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Energy and metabolic alterations in predisposition to pheochromocytomas and paragangliomas: the so-called Warburg (and more) effect, 15 years on.
    Neumann HP; de Herder W
    Endocr Relat Cancer; 2015 Aug; 22(4):E5-7. PubMed ID: 26273100
    [No Abstract]   [Full Text] [Related]  

  • 14. GROWTH RATE OF PARAGANGLIOMAS RELATED TO GERMLINE MUTATIONS OF THE SDHX GENES.
    Michałowska I; Ćwikła JB; Michalski W; Wyrwicz LS; Prejbisz A; Szperl M; Nieć D; Neumann HP; Januszewicz A; Pęczkowska M
    Endocr Pract; 2017 Mar; 23(3):342-352. PubMed ID: 27967220
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Genotype-Dependent Brown Adipose Tissue Activation in Patients With Pheochromocytoma and Paraganglioma.
    Puar T; van Berkel A; Gotthardt M; Havekes B; Hermus AR; Lenders JW; van Marken Lichtenbelt WD; Xu Y; Brans B; Timmers HJ
    J Clin Endocrinol Metab; 2016 Jan; 101(1):224-32. PubMed ID: 26574955
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Molecular markers of paragangliomas/pheochromocytomas.
    Zhikrivetskaya SO; Snezhkina AV; Zaretsky AR; Alekseev BY; Pokrovsky AV; Golovyuk AL; Melnikova NV; Stepanov OA; Kalinin DV; Moskalev AA; Krasnov GS; Dmitriev AA; Kudryavtseva AV
    Oncotarget; 2017 Apr; 8(15):25756-25782. PubMed ID: 28187001
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Genotype-specific differences in the tumor metabolite profile of pheochromocytoma and paraganglioma using untargeted and targeted metabolomics.
    Rao JU; Engelke UF; Sweep FC; Pacak K; Kusters B; Goudswaard AG; Hermus AR; Mensenkamp AR; Eisenhofer G; Qin N; Richter S; Kunst HP; Timmers HJ; Wevers RA
    J Clin Endocrinol Metab; 2015 Feb; 100(2):E214-22. PubMed ID: 25459911
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunohistochemistry for SDHB triages genetic testing of SDHB, SDHC, and SDHD in paraganglioma-pheochromocytoma syndromes.
    Gill AJ; Benn DE; Chou A; Clarkson A; Muljono A; Meyer-Rochow GY; Richardson AL; Sidhu SB; Robinson BG; Clifton-Bligh RJ
    Hum Pathol; 2010 Jun; 41(6):805-14. PubMed ID: 20236688
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical implications of the oncometabolite succinate in SDHx-mutation carriers.
    Eijkelenkamp K; Osinga TE; Links TP; van der Horst-Schrivers ANA
    Clin Genet; 2020 Jan; 97(1):39-53. PubMed ID: 30977114
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pheochromocytomas and Paragangliomas: An Update on Recent Molecular Genetic Advances and Criteria for Malignancy.
    Guo Z; Lloyd RV
    Adv Anat Pathol; 2015 Sep; 22(5):283-93. PubMed ID: 26262510
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.